Dianthus Therapeutics, Inc.

US$86.03As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:DNTHHealthcare
Country USA
PE (Fwd) •••
TSR 3Y CAGR 80.75%
Div yield —
ROE (22.61%)
Biotechnology
Beta (5Y) 0.26
PE TTM —
TSR TTM 145.94%
Mkt cap US$4.845B
ROIC (16.48%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$90
4.46%
467.72%
Hold 1|0|6|12|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
2.33
2.32
2.29
2.52
22.56%
15.18%
1.79%
11.55%
Revenue$M
308.7
327.2
331.0
324.9
8.13%
15.60%
11.17%
3.12%
Peers (US$4.845B)
Cap (US$)
PE
5.040B
—
Capital
TTM
5Y
10Y
Leveragex
0.815
0.949
0.681
EBIT/Intx
0.698
0.512
0.529
Own earn%
(31.47)
101.00
79.66
Sh yield%
19.78
19.82
19.90
Owners
Insiders/Inst%
6.15
34.08
Short interest%
1.24
SBC / revenue%
4.10
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
1–13
$1 testx
0.0
Incr. ROIC%
3